
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2296221/publications.pdf Version: 2024-02-01



Ιοςà Ο Μ Μλτà Ος

#	Article	IF	CITATIONS
1	Glutaminase isoforms expression switches microRNA levels and oxidative status in glioblastoma cells. Journal of Biomedical Science, 2021, 28, 14.	7.0	11
2	Antioxidant responses related to temozolomide resistance in glioblastoma. Neurochemistry International, 2021, 149, 105136.	3.8	17
3	Tumor Metabolome: Therapeutic Opportunities Targeting Cancer Metabolic Reprogramming. Cancers, 2021, 13, 314.	3.7	2
4	Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer. Seminars in Cell and Developmental Biology, 2020, 98, 34-43.	5.0	84
5	Glutaminases regulate glutathione and oxidative stress in cancer. Archives of Toxicology, 2020, 94, 2603-2623.	4.2	38
6	Nuclear Translocation of Glutaminase GLS2 in Human Cancer Cells Associates with Proliferation Arrest and Differentiation. Scientific Reports, 2020, 10, 2259.	3.3	26
7	Metabolic Reprogramming of Cancer by Chemicals that Target Glutaminase Isoenzymes. Current Medicinal Chemistry, 2020, 27, 5317-5339.	2.4	26
8	The Epithelial to Mesenchymal Transition Promotes Glutamine Independence by Suppressing GLS2 Expression. Cancers, 2019, 11, 1610.	3.7	31
9	Dysregulation of glutaminase and glutamine synthetase in cancer. Cancer Letters, 2019, 467, 29-39.	7.2	107
10	Glutaminase isoenzymes in the metabolic therapy of cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1870, 158-164.	7.4	63
11	Glutamine Addiction In Gliomas. Neurochemical Research, 2017, 42, 1735-1746.	3.3	64
12	Glutamate and Brain Glutaminases in Drug Addiction. Neurochemical Research, 2017, 42, 846-857.	3.3	35
13	MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Cancer Cell, 2017, 32, 71-87.e7.	16.8	373
14	Glutaminases. Advances in Neurobiology, 2016, 13, 133-171.	1.8	23
15	Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia. Nature Medicine, 2015, 21, 1182-1189.	30.7	180
16	Expression of Gls and Gls2 glutaminase isoforms in astrocytes. Glia, 2015, 63, 365-382.	4.9	45
17	Canceromics Studies Unravel Tumor's Glutamine Addiction After Metabolic Reprogramming. , 2015, , 257-286.		5
18	Both GLS silencing and GLS2 overexpression synergize with oxidative stress against proliferation of glioma cells. Journal of Molecular Medicine, 2014, 92, 277-290.	3.9	74

#	Article	IF	CITATIONS
19	Mammalian glutaminase isozymes in brain. Metabolic Brain Disease, 2013, 28, 133-137.	2.9	14
20	Metabolic changes in cancer cells upon suppression of MYC. Cancer & Metabolism, 2013, 1, 7.	5.0	54
21	Glutaminase Isoenzymes as Key Regulators in Metabolic and Oxidative Stress Against Cancer. Current Molecular Medicine, 2013, 13, 514-534.	1.3	161
22	Oxidative stress in apoptosis and cancer: an update. Archives of Toxicology, 2012, 86, 1649-1665.	4.2	290
23	The Metabolic Profile of Tumors Depends on Both the Responsible Genetic Lesion and Tissue Type. Cell Metabolism, 2012, 15, 157-170.	16.2	553
24	Analysis of Tumor Metabolism Reveals Mitochondrial Glucose Oxidation in Genetically Diverse Human Glioblastomas in the Mouse Brain InÂVivo. Cell Metabolism, 2012, 15, 827-837.	16.2	459
25	Mammalian Glutaminase Gls2 Gene Encodes Two Functional Alternative Transcripts by a Surrogate Promoter Usage Mechanism. PLoS ONE, 2012, 7, e38380.	2.5	44
26	Sulphur-containing non enzymatic antioxidants therapeutic tools against cancer. Frontiers in Bioscience - Scholar, 2012, S4, 722-748.	2.1	37
27	Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 8674-8679.	7.1	411
28	Roles of dioxins and heavy metals in cancer and neurological diseases using ROS-mediated mechanisms. Free Radical Biology and Medicine, 2010, 49, 1328-1341.	2.9	227
29	Brain glutaminases. Biomolecular Concepts, 2010, 1, 3-15.	2.2	11
30	Glutamine homeostasis and mitochondrial dynamics. International Journal of Biochemistry and Cell Biology, 2009, 41, 2051-2061.	2.8	123
31	A novel glutaminase isoform in mammalian tissues. Neurochemistry International, 2009, 55, 76-84.	3.8	56
32	New insights into brain glutaminases: Beyond their role on glutamatergic transmission. Neurochemistry International, 2009, 55, 64-70.	3.8	33
33	Natural Antioxidants: Therapeutic Prospects for Cancer and Neurological Diseases. Mini-Reviews in Medicinal Chemistry, 2009, 9, 1202-1214.	2.4	52
34	Intracellular redox status and oxidative stress: implications for cell proliferation, apoptosis, and carcinogenesis. Archives of Toxicology, 2008, 82, 273-299.	4.2	387
35	Antisense glutaminase inhibition modifies the Oâ€GlcNAc pattern and flux through the hexosamine pathway in breast cancer cells. Journal of Cellular Biochemistry, 2008, 103, 800-811.	2.6	43
36	Expression of functional human glutaminase in baculovirus system: Affinity purification, kinetic and molecular characterization. International Journal of Biochemistry and Cell Biology, 2007, 39, 765-773.	2.8	39

#	Article	IF	CITATIONS
37	Glutaminase: A multifaceted protein not only involved in generating glutamate. Neurochemistry International, 2006, 48, 465-471.	3.8	69
38	Pathways from glutamine to apoptosis. Frontiers in Bioscience - Landmark, 2006, 11, 3164.	3.0	60
39	Anti-oxidant enzyme activities and expression and oxidative damage in patients with non-immediate reactions to drugs. Clinical and Experimental Immunology, 2006, 145, 287-295.	2.6	16
40	Identification of genes downregulated in tumor cells expressing antisense glutaminase mRNA by differential display. Cancer Biology and Therapy, 2006, 5, 54-58.	3.4	11
41	Co-expression of glutaminase K and L isoenzymes in human tumour cells. Biochemical Journal, 2005, 386, 535-542.	3.7	104
42	Inhibition of glutaminase expression increases Sp1 phosphorylation and Sp1/Sp3 transcriptional activity in Ehrlich tumor cells. Cancer Letters, 2005, 218, 91-98.	7.2	12
43	Sensitisation of Ehrlich ascitic tumour cells to methotrexate by inhibiting glutaminase. Anticancer Research, 2005, 25, 3315-20.	1.1	5
44	Antisense glutaminase inhibition decreases glutathione antioxidant capacity and increases apoptosis in Ehrlich ascitic tumour cells. FEBS Journal, 2004, 271, 4298-4306.	0.2	118
45	Genomic organization and transcriptional analysis of the human l-glutaminase gene. Biochemical Journal, 2003, 370, 771-784.	3.7	29
46	Glutamine and its relationship with intracellular redox status, oxidative stress and cell proliferation/death. International Journal of Biochemistry and Cell Biology, 2002, 34, 439-458.	2.8	281
47	Chemical intermediates scavengers in the therapy of allergic diseases. Research on Chemical Intermediates, 2001, 27, 297-304.	2.7	0
48	Allergy to drugs: antioxidant enzymic activities, lipid peroxidation and protein oxidative damage in human blood. , 2000, 18, 77-84.		30
49	Effects of antioxidant enzymes in the molecular control of reactive oxygen species toxicology. Toxicology, 2000, 153, 83-104.	4.2	1,219
50	Interrelationship between oxidative damage and antioxidant enzyme activities: an easy and rapid experimental approach. Biochemical Education, 2000, 28, 93-95.	0.1	5
51	Interrelationship between oxidative damage and antioxidant enzyme activities: an easy and rapid experimental approach. Biochemical Education, 2000, 28, 93-95.	0.1	10
52	Role of reactive oxygen species in apoptosis: implications for cancer therapy. International Journal of Biochemistry and Cell Biology, 2000, 32, 157-170.	2.8	639
53	Chemical and biological activity of free radical â€~scavengers' in allergic diseases. Clinica Chimica Acta, 2000, 296, 1-15.	1.1	62
54	Antioxidant activity levels and oxidative stress as blood markers of allergic response to drugs. Biochemistry and Cell Biology, 2000, 78, 691-698.	2.0	2

#	Article	IF	CITATIONS
55	Antioxidant enzymes and human diseases. Clinical Biochemistry, 1999, 32, 595-603.	1.9	1,656
56	Antioxidant Enzymatic Activities in Human Blood Cells after an Allergic Reaction to Pollen or House Dust Mite. Blood Cells, Molecules, and Diseases, 1999, 25, 103-109.	1.4	59
57	Antioxidant enzymes and their implications in pathophysiologic processes. Frontiers in Bioscience - Landmark, 1999, 4, d339-345.	3.0	199
58	Structure/function relationship studies on the T/S residues 173–177 of rat ODC. BBA - Proteins and Proteomics, 1998, 1386, 113-120.	2.1	2
59	Mammalian l-amino acid decarboxylases producing 1,4-diamines: analogies among differences. Trends in Biochemical Sciences, 1994, 19, 318-319.	7.5	38
60	Expression of different mitogen-regulated protein/proliferin mRNAs in Ehrlich carcinoma cells. FEBS Letters, 1994, 349, 343-348.	2.8	8
61	The induction of ornithine decarboxylase by ornithine takes place at post-transcriptional level in perifused Ehrlich carcinoma cells. Cancer Letters, 1992, 67, 187-192.	7.2	5
62	Chlorpheniramine inhibits the ornithine decarboxylase induction of Ehrlich carcinoma growing in vivo. FEBS Letters, 1992, 305, 260-264.	2.8	27
63	Simultaneous fluoremetric determination of intracellular polyamines separated by reversed-phase high-performance liquid chromatography. Agents and Actions, 1992, 36, 17-21.	0.7	26
64	Polyamine metabolism regulation by histamine and other biogenic amines in Ehrlich carcinoma cells. Agents and Actions, 1992, 36, C380-C383.	0.7	2
65	Regulation by 1,4-diamines of the ornithine decarboxylase activity induced by ornithine in perifused tumor cells. Biochemical Pharmacology, 1991, 42, 1045-1052.	4.4	16
66	Histamine and serotonin inhibit induction of ornithine decarboxylase by ornithine in perifused Ehrlich ascites tumour cells. FEBS Letters, 1989, 250, 257-261.	2.8	15
67	Altered ornithine metabolism in tumor-bearing mice. Life Sciences, 1989, 45, 1877-1884.	4.3	17